Page 21234..1020..»

Category : Testosterone Physicians

Go or no go? Agile and Lipocine hope to make it third time lucky – Vantage

After some huge US approvals in recent months, November is shaping up to be quieter. There are no decisions on future blockbusters set for next month, Vantages regular PDUFA analysis shows.

However, some of the upcoming verdicts will still be a big deal for the companies involved. This includes Agile Therapeutics and Lipocine, which hope to bounce back from complete response letters for the Twirla contraceptive patch and the testosterone replacement therapy Tlando respectively.

Twirla's chances of getting approved got a boost yesterday, with an FDA advisory committee voting 14-1 that the benefits of the projects outweigh its risks an unexpected outcome given scathing briefing documentsreleased on Monday. The agency questioned the patch's efficacy, thoughAgile put unimpressive results from the pivotal Secure trial down to a high number of obese participants, in whom contraceptives do not work as well.

The FDA questioned Twirla's efficacy even in non-obese women, however, and also raised doubts about whether the project is a low-dose, and therefore potentially safercontraceptive, as Agile has claimed. Shares in the company recovered today after slumping on the briefing docs, but investors' wild ride might not be over yet.

Meanwhile, Lipocine will hope that an ambulatory blood pressure study will answer questions raised in the FDAs May 2018 CRL. The company believes that Tlando, an oral therapy, will have an edge over injectable testosterone products. Another oral contender got the FDA nod earlier this year, Clarus Therapeutics Jatenzo, andLipocine is embroiled in a legal wrangle with Clarus over intellectual property.

A project that should get a smoother ride is Shionogis S-649266, or cefiderocol, a novel antibiotic targeting Gram-negative pathogens. The project recently got an adcom thumbs up, with panellists voting14-2 in favour ofapproval for patients with complicated urinary tract infections and limited or no alternative treatment options.

The project has also shown promise in pneumonia. Still, as with many antibiotics, especially those saved for drug-resistant infections, succeeding commercially will be trickier.

Meanwhile, Redhill Biopharmas Talicia, which combines two antibiotics and a proton pump inhibitor, is awaiting a verdict in Helicobacter pylori infection. It has a good shot after a positive result in the Eradicate Hp2 trial, and a recent tie-up with Cosmo Pharmaceuticals should also give Redhill sufficient funds for launch.

However, sales expectations are not huge, with EvaluatePharma consensus predicting $27m in 2024.

Supplements

As for potential supplementary approvals, Lilly and Boehringer hope to get cardiovascular data on the label of their DPPIV inhibitor Tradjenta. However, the product has only shown noninferiority to placebo in the Carmelina study; with other diabetes drugs like the SGLT2s and GLP1s showing cardioprotective effects, the DPPIV class has been put in the shade.

Other decisions, including a verdict on Pfizers Humira biosimilar, continue to be expected sometime in the fourth quarter.

The biggest regulatory event of November is not an approval but rather an advisory committee meeting, for Amarins Vascepa. On November 14 panellists will consider the products expanded use for the reduction of cardiovascular events in patients with high triglycerides; the FDA had previously been expected to make a call here in September.

EvaluatePharma consensus forecasts 2024 Vascepa sales of $2.2bn, but Leerink analysts believe that, if the drug does get expanded approval, US revenues could exceed $4bn.

Original post:
Go or no go? Agile and Lipocine hope to make it third time lucky - Vantage

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -…

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new Reserach Report

Testosterone Replacement Therapy Market2019 Research report contains a qualified and in-depth examination of Testosterone Replacement Therapy Market. At first, the report provides the current Testosterone Replacement Therapy business situation along with a valid assessment of the Testosterone Replacement Therapy business. Testosterone Replacement Therapy report is partitioned based on driving Testosterone Replacement Therapy players, application and regions. The progressing Testosterone Replacement Therapy economic situations are additionally discovered in the report.

Short Description About Testosterone Replacement Therapy Market :

Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.

Get Sample PDF of reporthttps://www.360researchreports.com/enquiry/request-sample/13836798

The research covers the current market size of the Testosterone Replacement Therapy market and its growth rates based on 5-year records with company outline ofKey players/manufacturers:

Scope Of The Report :

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%. Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new research study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13836798

Report further studies the Testosterone Replacement Therapy market development status and future trend across the world. Also, it splits Testosterone Replacement Therapy market by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Testosterone Replacement Therapy in these regions, from 2014 to 2024, covering

The Testosterone Replacement Therapy market report provides answers to the following key questions:

Purchase this report (Price 3480 USD for a single-user license) https://www.360researchreports.com/purchase/13836798

Major Points from Table of Contents:

1 Market Overview1.1 Testosterone Replacement Therapy Introduction1.2 Market Analysis by Type1.3 Market Analysis by Applications1.4 Market Dynamics1.4.1 Market Opportunities1.4.2 Market Risk1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview2.4.2 Testosterone Replacement Therapy Type and Applications2.4.2.1 Product A2.4.2.2 Product B

3.Global Testosterone Replacement Therapy Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

3.1 Global Testosterone Replacement Therapy Sales and Market Share by Manufacturer (2017-2018)3.2 Global Testosterone Replacement Therapy Revenue and Market Share by Manufacturer (2017-2018)3.3 Market Concentration Rate3.3.1 Top 3 Testosterone Replacement Therapy Manufacturer Market Share in 20183.3.2 Top 6 Testosterone Replacement Therapy Manufacturer Market Share in 20183.4 Market Competition Trend

4 Global Testosterone Replacement Therapy Market Analysis by Regions

4.1 Global Testosterone Replacement Therapy Sales, Revenue and Market Share by Regions4.1.1 Global Testosterone Replacement Therapy Sales and Market Share by Regions (2014-2019)4.1.2 Global Testosterone Replacement Therapy Revenue and Market Share by Regions (2014-2019)4.2 North America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.3 Europe Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.4 Asia-Pacific Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 South America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 Middle East and Africa Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)

6 Testosterone Replacement Therapy Market Forecast (2019-2024)6.1 Global Testosterone Replacement Therapy Sales, Revenue and Growth Rate (2019-2024)6.2 Testosterone Replacement Therapy Market Forecast by Regions (2019-2024)6.3 Testosterone Replacement Therapy Market Forecast by Type (2019-2024)6.3.1 Global Testosterone Replacement Therapy Sales Forecast by Type (2019-2024)6.3.2 Global Testosterone Replacement Therapy Market Share Forecast by Type (2019-2024)6.4 Testosterone Replacement Therapy Market Forecast by Application (2019-2024)6.4.1 Global Testosterone Replacement Therapy Sales Forecast by Application (2019-2024)6.4.2 Global Testosterone Replacement Therapy Market Share Forecast by Application (2019-2024)

6.Sales Channel, Distributors, Traders and Dealers6.1 Sales Channel6.1.1 Direct Marketing6.1.2 Indirect Marketing6.1.3 Marketing Channel Future Trend6.2 Distributors, Traders and Dealers

7. Research Findings and Conclusion

8. Appendix8.1 Methodology8.2 Data Source

Continued..

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies

See the article here:
Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -...

Recommendation and review posted by Alexandra Lee Anderson

Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 – Zebvo

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

Go here to read the rest:
Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 - Zebvo

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market Outlook: Heading To the Clouds – Daily Market Insight

Europe Testosterone Replacement Therapy study will help you investigate a detailed division of the market by the end user/industry, by best in class product type and by geography with creation, income, utilization, export & import data in these areas, crunching historical data along with primaries and opinion leaders and industry experts interview and estimate with detailed driving factors for forcasted period.

Get Sample Report PDF With More Details And Graph @https://www.htfmarketreport.com/sample-report/1631438-europe-testosterone-replacement-therapy-market-1The Europe Testosterone Replacement Therapy is relied upon to come to an expected $XX.X billion by 2025 and it is a gauge to develop at a CAGR of X.X% for forecast period. This report centers around top makers in the Europe Testosterone Replacement Therapy, with generation, value, income, and market share for every producer/manufacturers.

Top Testosterone Replacement Therapy Manufacturers:AbbVie, Allergan, Eli Lilly, Endo International, Acerus Pharmaceutical Corporation, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx & Teva Pharmaceuticals.Testosterone Replacement Therapy Report Focusing By Types:, Gels, Injectables & Patches

Testosterone Replacement Therapy Report Focusing By Applications:Hospitals & Clinics

Testosterone Replacement Therapy Report Focusing By Regions:Germany, France, UK, Russia, Italy, Spain & Benelux

For Detail View Of TOC (Table Of Content) @https://www.htfmarketreport.com/reports/1631438-europe-testosterone-replacement-therapy-market-1Testosterone Replacement Therapy Report shows a detailed overview of the market by strategy for study, mix, and data evaluated from different sources. The pros have presented the various appearances of the market with a particular, base on recognizing Testosterone Replacement Therapy business influencers.

Have Any Query? Ask Our Expert @https://www.htfmarketreport.com/enquiry-before-buy/1631438-europe-testosterone-replacement-therapy-market-1This Report Will Give a Nitty-Gritty Evaluation of Significantly Accompanying:

Item outline and extent of Europe Testosterone Replacement TherapySignificant players in the Europe Testosterone Replacement Therapy Market.Europe Testosterone Replacement Therapy players/providers Profiles and Sales information.Testosterone Replacement Therapy Marketing procedure examination and improvement patterns.Testosterone Replacement Therapy Market impact factor examination.Developing specialty fragments and local Testosterone Replacement Therapy markets.An experimental evaluation of the direction of the Testosterone Replacement Therapy.Real changes in Testosterone Replacement Therapy elements/ sub industry segments.Chronicled, present, and imminent size of the Testosterone Replacement Therapy from the point of view of both revenue and sales volume and average price.

It is vital for an organization to have the capacity to catch the mindshare of their gathering of people as it is characteristic for an organization which is planning to see a development in the Europe Testosterone Replacement Therapy. This is conceivable through a knowledgeable network administration and develops an advertising plan for the Europe Testosterone Replacement TherapyIndustry.

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=1631438Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

Original post:
Testosterone Replacement Therapy Market Outlook: Heading To the Clouds - Daily Market Insight

Recommendation and review posted by Alexandra Lee Anderson

After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) – Stock Investor

After its stock gained a third of its value over the past 60 days, AbbVie, Inc. (NYSE:ABBV) beat revenue and earnings expectations and obtained potential fuel that may allow it to extend its current share price uptrend.

The companys share price exhibited steady growth and more than doubled from its initial public opening (IPO) price of $34.40 to more than $75 by August 2017. After a brief spike to nearly $125 over the next five months, the share price reversed direction and gave back those quick gains by the beginning of 2019.

However, the chart below illustrates that the share price was still at its long-term uptrend in January 2019. However, after dropping further, the share price has been rising steadily since mid-August 2019 and the positive results from the current quarterly report should continue to power the current share price recovery.

Released on November 1, AbbVies report for the third quarter of 2019 which ended on September 30, 2019 revealed a 3% increase in worldwide net revenues to $8.48 billion. Diluted earnings per share (EPS) were $1.26. The adjusted EPS of $2.33 was nearly 9% above the $2.14 adjusted EPS from the same period last year and beat analysts earnings expectations of $2.29 by 1.75%. After missing earnings estimates by 2% in the last quarter of 2018, AbbVie managed to beat earnings expectations in the last three consecutive quarters and four times in the last five periods.

The companys current $1.07 quarterly dividend is 11.5% higher than the companys $0.96 payout from the same quarter last year. This new quarterly payout corresponds to a $4.28 annualized distribution. Using the $79.55 share price as of closing on October 31, 2019, the current payout is equivalent to a 5.38% forward dividend yield. This is 32.5% above the companys own 4.06% yield average over the past five years.

Additionally, AbbVies current yield level is the highest among the companys peers in the Major Drug Manufacturers market segment. Furthermore, AbbVies current yield is at least 20% higher than the segments only other yields in excess of 4% Takeda Pharmaceutical Co Ltd (NYSE:TAK) at 4.51% and GlaxoSmithKline Plc (NYSE:GSK) at 4.37%. As the segments top value, AbbVies current yield is nearly triple the segments 1.8% simple average, as well as nearly double the 2.8% average yield of the segments only dividend paying companies. Furthermore, in a sector that is renowned for its low dividend payouts, AbbVies current yield is nearly 10-fold higher than the 0.52% simple yield average of the entire Health Care sector.

As a separate legal entity, AbbVies current streak of consecutive annual dividend hikes only goes back six years. However, the companys history of dividend payouts as part of Abbot Labs goes back several decades. In 2013 the year of the divestiture from Abbott Laboratories the two companies paid individual dividends. However, the sum of the two payouts was higher than Abbott Laboratories total dividend payout over the previous year. Furthermore, both companies have continued to hike their respective annual dividends every year since 2013.

Therefore, we can give credit for the past dividend hikes to both companies and consider the annual dividend hikes since 2012 to be a continuation of the previous streak. Under that assumption, AbbVie has boosted its annual dividend payout for the past 46 consecutive years. Since AbbVie is a component of the S&P 500 Index and meets all the other market capitalization, liquidity and trading volume requirements, we can include the company as a part of the S&P 500 Dividend Aristocrats group.

Even disregarding the dividend distributions that were delivered prior to 2013, AbbVie has enhanced its annual dividend distribution amount by nearly 170% just over the past six years that it has been its own business entity. That level of advancement corresponds to an average growth rate of nearly 18% per year.

The share price entered the trailing 12-month period by riding the downtrend that began in January 2018. After passing through its 52-week low of $94.27 on November 30, 2018, the share price declined by nearly 50% before reaching the 52-week low of $62.98 on August 15, 2019.

However, since reversing its trend in mid-August, the share price has recovered more than half of its losses since the November peak and closed on October 31, 2019, at $79.55. This was flat with the price level of one year ago and 26% higher than the 52-week low from August. Furthermore, the share price surged 3.5% on positive financial results in just the first hour of trading on Nov. 1. The share price trailed off a little afterwards even though it held on to a 2.5% gain as of noon on the same day.

With the share price at last years levels, dividend income payouts have contributed all of the total gains of approximately 5% over the trailing 12 months. However, capital gains have contributed most of the total gains of more than 60% over the past three years.

Headquartered in North Chicago, Illinois, and founded when Abbott Labs (NYSE:ABT) divested its proprietary pharmaceutical business in 2013, AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products. The most prominent pharmaceutical brands in the companys current portfolio are HUMIRA for the treatment of autoimmune diseases, IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia and VIEKIRA PAK for the treatment of adults with hepatitis C. Additionally, AbbVie offers pharmaceutical treatments for HIV, hypothyroidism, prostate cancer, endometriosis, anemia, Parkinsons disease and multiple sclerosis, as well as treatments for testosterone replacement therapy and pancreatic enzyme therapy for exocrine pancreatic insufficiency.

Ned Piplovicis the assistant editor of website content at Eagle Financial Publications. He graduated from Columbia University with a Bachelors degree in Economics and Philosophy. Prior to joining Eagle, Ned spent 15 years in corporate operations and financial management. Ned writes forwww.DividendInvestor.comandwww.StockInvestor.com.

See the rest here:
After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) - Stock Investor

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market Research Study by Porters Five Forces Analysis with CAGR of -2.46% & Forecast to 2023 – Joliet Observer

The Testosterone Replacement Therapy Market Report provides Growth history, Sales channel, Manufacturers profiled in Testosterone Replacement Therapy industry, Market share of product and scope of a region in detail. The Market report also consists of key drivers and limiting factors affect the Testosterone Replacement Therapy Market Growth, Change in industry Trends or challenges faced by Testosterone Replacement Therapy Manufacturers in forecast years.Testosterone Replacement Therapy Market report will help you take well-versed decisions, understand opportunities, plan effective business strategies, plan new projects, analyze drivers and give you a vision on the industry forecast.

GetA Sample PDF Of Report

About this marketIncreased awareness about hypogonadism among the public and primary care physicians will drive the market. Globally, different organizations are working on initiatives to increase patient awareness of hypogonadism and available treatment options. The vendors are actively taking part in the awareness campaign to educate the population about the diagnoses and treatment for hypogonadism. Also, organizations are increase awareness about hypogonadism among medical professionals. They release clinical practice guidelines on testosterone therapy. The testosterone replacement therapy market growth at a CAGR of more than (2%) during the forecast period.

The report splits the global Testosterone Replacement Therapy market into theAmericas, Asia-Pacific, Europe, the Middle East, and Africa Region. The Testosterone Replacement Therapy Market report useful for forecasters, marketers, industry specialists & consultants, sales, product managers, Business Development Advisors, Strategy Advisors, manufactures, potential investors, key executive (CEO and COO) to provides a detailed analysis of the key players in the market which provides a company overview, financial overview, service offering, different strategies used by them, and comprehensive SWOT analysis of

Researcher project Testosterone Replacement Therapy market to grow at a CAGR of -2.46% during the period 2019-2023.

Feel Free to Ask Question Before Purchasing the Report

The worldwide and regional Testosterone Replacement Therapy market elements are precisely explained which helps to understand advancing of business trends, drivers, opportunities, and difficulties for the worldwide Testosterone Replacement Therapy market.

Market Overview

Competitive Landscape

The Porters five forces analysis included in the report educates buyer on the current situations along with anticipated future Testosterone Replacement Therapy market size.

Some of the key topics covered in the report include:

Purchase This Report (Price 2500 USD for a Single-User License)

The CAGR of each segment in the Testosterone Replacement Therapy market along with global market (as a whole) is explained with great ease. Also, global and regional Testosterone Replacement Therapy market supply chain analysis provides vital info about producers, distributers and key end-users in the market. It also explains import-export situations, affecting factors, etc. to fully and deeply reveal market situations.

Table of Contents included in Testosterone Replacement Therapy Market Report PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction- Market outline

PART 05: Market landscape Market overview, Market size, and forecast, Five forces analysis

PART 06: Market segmentation by end-user industry

PART 07: Market segmentation by application

PART 08: Geographical segmentation Testosterone Replacement Therapy market in APAC, Europe, North America & ROW

PART 09: A Decision framework

For More Chapters Click Here

Contact Us:

Be sure to follow us on Linkedin at @ 360 Market Updates for more on growth research of the market.

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +44 203 239 8187/ +1 424 253 0807

Excerpt from:
Testosterone Replacement Therapy Market Research Study by Porters Five Forces Analysis with CAGR of -2.46% & Forecast to 2023 - Joliet Observer

Recommendation and review posted by Alexandra Lee Anderson

Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and…

You may want to sort out your chronic pain, look and feel younger, or maybe you would like to increase your energy level so you can pursue your goals.

Well, thankfully the team at Richardson Pain & Wellness is ready and able to help you do it, their doctors have many years of experience with custom-made wellness plans suited to each patients individual needs and wants, ensuring that they not only feel renewed in our office but for many years to come. All you have to do is set up an appointment with one of the doctors, and they will help you get started and create a plan to suit your needs and interests.

The pain clinic Richardson offers testosterone replacement therapy and hormone replacement therapy at Richardson. If tests show that you do have low T and you notice the condition taking over your life, then you should consider hormone replacement therapy in Richardson to supplement the bodys production of testosterone to levels of young adulthood.

Furthermore, replacement therapy may lead to desired results, such as greater muscle mass and a stronger sex drive.However, Richardson Pain & Wellness the testosterone therapy to treat low T is vital is surprised to make you aware. Due to the mental and physical risks may develop with self-administered artificial or synthetic testosterone.The testosterone therapy Richardson is suitable for those with low testosterone, call Richardson Pain & Wellness today to schedule a consultation.

Also, Richardson offers the residents of medical weight loss programs Richardson, which they designed with care and precision to suit each patient. So, what does the weight loss program entail? Well, they create a customized diet, exercise plan, and supplement program, they believe it is essential to focus on workingwith their body for weight loss, not against it.

Richardson Pain & Wellness creates a weight loss program that is put together by two doctors alongside a registered dietitian. These professionals have years of experience in the field of wellness and pain management. For instance, Janel Kobza-Chukhman has over 15 years of nutrition counseling experience. A considerable advantage of Richardson Pain & Wellness is that they provide you with all three elements; a diet plan, an exercise plan, and supplements. Whats even better is the result you achieve after all the hard work of keeping to your specified program.

Richardson believes the key to healthy weight loss is following a plan that is specially made for you, and they are proud of the weight-loss programs they provide for their clients.

Contact the Richardson pain clinic today if you would like to book an appointment and have one of their experienced doctors custom make a wellness plan to suit your needs or if you want to start your weight-loss journey today. Ring the clinic on (972) 907-1125, or you can email alignrightchiropractic@gmail.com to schedule an appointment.

Source:https://thenewsfront.com/richardson-pain-wellness-offering-testosterone-replacement-therapy-male-hormone-replacement-therapy-medically-assisted-weight-loss-and-conservative-pain-management-in-richardson-texas/

See original here:
Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and...

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 – Statsflash

The global testosterone replacement therapy market rides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights, Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report, Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

Visit link:
Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 - Statsflash

Recommendation and review posted by Alexandra Lee Anderson

The Good, the Bad and the Ugly of UFC on ESPN 6 – Sherdog.com

Lauzon turned back time by defeating JonathanPearce. It was the perfect way to say goodbye to the sport forLauzon, who has sustained a great deal of damage over the course ofhis career and stepped into the cage riding a three-fight losingstreak. In front of his beloved Bostonians and with the samesignature violence that makes him a surefire Hall of [emailprotected]#$%&gAwesome candidate, Lauzon big-brothered the up and comer withground-and-pound from a half nelson. While Lauzon was hesitant tocommit to retirement immediately after the fight, UFC PresidentDana White seemed ready to encourage him to end his career on ahigh note. Lauzon turned what looked like a setup match for thenext generation -- Pearce was on a five-fight winning streak thatincluded an appearance on Dana Whites Contender Series and twoothers in Bellator MMA -- into the perfect swan song.

Rosa and Costa entered the arena hoping to the right ship, as bothmen had experienced defeats in their previous outings. In stylepairings that promised fireworks against MannyBermudez and the ironically named BostonSalmon, Rosa and Costa came out in the winning side of thosefireworks. With the exception of KyleBochniak, who was outclassed by an impressively poised SeanWoodson, the city managed to enjoy home-cooked victories. Whilethe UFC has rightfully received criticism for not booking mainevents in locations more appropriate for the fighters, it does agood job of keeping a local feel to the undercards. Results likethis help elevate an otherwise routine event.

Unfortunately for Weidman, the extra 20 pounds on the scale didnothing to resuscitate his career. Reyes heavy hands and technicalacumen proved too steep of a mountain to climb, as the formerchampion fell victim to a backstepping left hand and follow-uphammerfists on the ground. Less than two minutes into the contest,Weidmans light heavyweight campaign came to a screeching halt. Hadthings gone differently, it seemed almost certain that theSerra-Longo Fight Team standout would have been tapped to standopposite Jon Jones in abattle over the light heavyweight title. Say what you will aboutwho would have been favored to win that fight, but Weidman wouldhave added name value to the blue corner that is not readilyavailable at 205 pounds. Similar to when rumors swirled aboutRockhold being fast tracked if he passed his first test in a higherweight class, the potential involving Weidman went unfulfilled andthe dominant champion was left to look elsewhere for a marqueematchup.

A victory over Reyes would have provided a simple answer to thequestion of what was next for Weidman, along with a built-in chanceto redeem the misfortune that has plagued his career in recentyears. Now, another decisive loss puts that question in bold print.There just is not an easy answer for Weidman at this point. Hecould elect to remain at 205 pounds. However, his ceiling seemspretty obvious. The damage he sustained in wars at 185 pounds didnot just magically go away with a move up in weight. Just like wewitnessed with James Vick atUFC Fight Night 161, the leap in weight may have come too late.Should Weidman decide to run it back at middleweight, he will facethe same challenges associated with his inability to absorbpunishment. The top names in the division would be no kinder to hischin, including KelvinGastelum, who managed to hurt Weidman badly before beingsubmitted two years ago. Plus, Weidman would be back to draininghis large frame again.

It seems likely that Weidman and his team will examine what lifeoutside of competition looks like. After being knocked out fivetimes in six fights and nearly suffering the same fate in his lonevictory during that stretch, it looks like we are witnessing theend of a great career.

Hardy has made four appearances inside the Octagon so far. Half ofthose them have gotten bogged down with rule-bending controversy.From a competitive standpoint, those controversies have distractedfrom his clear growth as a fighter under the direction of AmericanTop Team. Now, his taking two puffs from a prescribed inhalerbetween the second and third rounds has taken the conversation awayfrom the things he did right in the cage in Boston.

By adding more elements to his game, Hardy managed to outpoint thestubborn Ben Sosoli.Leg kicks from the outside, effective defensive footwork and theability to do something other than quickly blast his opponent tobits were on display. However, when he used his medication betweenrounds, it called the entire fight into question. Going thedistance for the first time and handling a consistent pace withoutmuch issue would normally something to commend for a fighter whosecareer mainly consists of short circuiting the opposition in quickfashion. How can we rightfully look at Hardy lasting the full 15minutes as a positive if he needed his asthma medication to doso?

The fault does not exclusively rest with Hardy or trainer Din Thomas,who was the primary target of Whites criticism after the fact.Granted, when most athletic commissions only allow water or in somecases an electrolyte-enhanced beverage like Gatorade in the corner,there is no reason to believe that medication that enhancescardiorespiratory function is permissible during a fight. However,the Massachusetts State Athletic Commission did plainly tell Hardyand his team that it was permitted. The level of confusion betweenthe commission (which quickly overturned the decision to ano-contest), UFC Vice President of Regulatory Affairs Marc Ratner,the commentary booth, media and amateur online investigators wastruly bizarre to witness. Is Albuterol allowed between rounds? Whatabout the potential abuse of asthma medication in relation tosports performance? Is Massachusetts clear enough about what is andis not allowed in competition? Why was the fight allowed tocontinue into that pivotal third frame in the first place?

As the infamous 1983 boxing match between Luis Resto and BillyCollins Jr. showed, asthma medication can be used a PED to increasecardio capacity. As the testosterone replacement therapy era of MMAshowed, fighters can and will abuse the use of therapeuticexemptions to gain a competitive edge. It sounds like a recipe fordisaster if the commission does not address this properly.

Clear improvement and two dominant wins from Hardy have beensandwiched between two displays of poor judgment. Those trustedwith overseeing the action in a responsible fashion get a solidfailing grade on clearly communicating the proper rules andhandling discrepancies as they arise. Once again, Hardysperformance inside the cage was overshadowed by other factors.

See the original post:
The Good, the Bad and the Ugly of UFC on ESPN 6 - Sherdog.com

Recommendation and review posted by Alexandra Lee Anderson

Testosterone Replacement Therapy Studies 2019

2018 saw a plethora of reports on testosterone replacement therapy, health risks, studies, trials, and types of TRT. Here at HGH doctor, our hormone replacement physicians keep up on the latest research to ensure we provide the best quality care to our clients. Part of our focus is passing new information and studies forward to you here on our website.

The results of one study on middle-aged and older men focused on the best type of treatment for fat-free mass (FFM) and muscle strength response. Men participating in the study received either intramuscular testosterone injections, transdermal TRT, or a placebo.

Although all forms of testosterone therapy showed positive improvements in FFM, total body strength, and lower and upper extremity strength, the changes seen were 3 to 5 times greater in the men who received testosterone injections rather than transdermal TRT. [1]

Testosterone therapy studies such as this one help our doctors choose the appropriate treatment for each person.

The Testosterone Therapy Trials in elderly men consisted of seven coordinated trials looking at the following areas:

We will report on these, as well as other trials and studies in this article.

Testosterone studies shed light on the benefits and safety of using testosterone replacement therapy.

For years, doctors steered men with or at greater risk of developing prostate cancer away from TRT. Even if a male had all the signs of low testosterone, many doctors believed that treatment with testosterone therapy would increase prostate cancer dangers. Luckily, there has been much research done in this area, showing the safety and benefits of TRT following prostate cancer treatment. Also, men who suffer from prostate enlargement or prostate cancer risks can also safely use testosterone therapy.

In the most recent testosterone replacement therapy studies, mounting evidence points to the safety of testosterone without reducing the risk of prostate cancer.

In a pooled analysis of 18 testosterone replacement therapy recent studies on 3,886 men diagnosed with prostate cancer, and 6,439 in the control group, there was no association between testosterone levels, DHT, and prostate cancer. [2, 3]

In a 2017 report, the Registry of Hypogonadism in Men reported that there was no increase in the odds of developing prostate cancer with the use of TRT. [4]

A 2013 study of men who underwent prostatectomy for prostate cancer found no increased risk of prostate cancer following testosterone therapy. [5]

In 2015, a study of men who underwent radiation therapy for prostate cancer followed up by testosterone therapy showed only a minor increase in serum PSA and a low rate of biochemical recurrence. [6]

Based on the current research, testosterone replacement therapy shows positive benefits for improving quality of life and well-being in men treated for prostate cancer.

With a multitude of testosterone replacement therapy studies reversing the prior concerns about cardiovascular risk, many men can improve their quality of life with TRT to treat the symptoms of hypogonadism.

Testosterone supports heart health through the production of red blood cells needed for circulation. Additionally, testosterone improves nitric oxide production crucial for proper insulin function and blood flow.

Nitric oxide is crucial to heart health and is made by the endothelium the lining of the blood vessels. Testosterone helps to lower LDL cholesterol to reduce the plaque clogging the arteries.

In 2017, a look at testosterone and the heart showed that low levels of testosterone might increase risk factors for metabolic syndrome, coronary artery disease (CAD), and type 2 diabetes. Testosterone replacement therapy helps to improve myocardial ischemia in males diagnosed with CAD. TRT also increases exercise capacity in men with congestive heart failure (CHF). Testosterone aids in weight loss and improving serum glucose levels and insulin resistance. This study reports that TRT reduces the risk of mortality in testosterone deficient men. [8]

Testosterone has many benefits for heart health, improving circulation, and reducing the risk of cardiovascular disease.

The study duration of one year consisted of receiving either testosterone gel or a placebo. Three different questionnaires every three months assessed sexual function. Results of the study showed that TRT had significant improvements for 10 out of 12 measures of sexual activity. [9, 10]

Testosterone replacement therapy studies for men with urinary symptoms such as urinary frequency, weak stream, urgency, straining to void, and other issues have found that benign prostatic hyperplasia (BPH) can impact urinary health. Prostate enlargement often occurs as men age, along with a decline in testosterone levels. Urinary issues can impact not only quality of life, but also overall health. Treatment with testosterone therapy has been shown to decrease nocturia (nighttime voiding) and improve urinary symptoms. [11]

A 2017 study of more than 650 men showed that testosterone therapy reduces weak urinary stream, nighttime waking to urinate, incomplete emptying of the bladder, and frequent urination. Additional benefits were found in erectile functions and quality of life. [12]

Testosterone has benefits for improved sexual functions as well as urinary health.

Reviewing testosterone replacement therapy studies allows our doctors to incorporate the latest research into patient treatment protocols. Low testosterone is frequently associated with the following medical conditions:

In the Physical Function Trial for men with hypogonadism, the focus was on walking distance as a measurement of testosterone benefits. TRT increased the fraction of distance walked, and the absolute increase in distance walked in 6 minutes.[13]

The Vitality Trial measured only the Functional Assessment of Chronic Illness Therapy fatigue scale, and while the results were not significant, the overall findings from the entire testosterone trials whose positive improvements on vitality, mood, and depression symptoms. However, a 2018 report found that testosterone replacement therapy reduces depressive symptoms except in individuals with major depressive disorder.[14]

The results of the Anemia Trials from these studies on testosterone therapy were extremely positive. In both men with explained and unexplained anemia, there was a considerable increase in hemoglobin concentration. The increase was associated with a significant change in the impression of vitality and general health in these men.

The Bone Trial purpose was to determine if TRT in older men could increase volumetric bone mineral density (vBMD) and bone strength. The outcome showed a total increase in vBMD of the trabecular bone in the spine as well as the whole bone vBMD. Hip strength also improved with TRT. Treatment with testosterone therapy could result in reduced risk of bone fractures for older men.

A surprising outcome of the Testosterone Therapy Trials is that there was not much in the way of cognitive benefits. However, other studies offer different findings. A double-blind, placebo-controlled study found modest improvement in global cognition.[15]

Testosterone replacement therapy can benefit physical ability, red blood cell production, and bone density.

Based on the many testosterone replacement therapy studies available for review today, we believe that the safe and supervised use of TRT can offer many benefits for middle-aged and older men. The key factor here is the need to engage in proper diagnostic testing for low testosterone and remain under doctor-supervision while receiving testosterone therapy.

To date, there is less research on testosterone therapy for women with Low T. A 2014 review of 20 randomized, placebo-controlled trials shows positive benefits for sexual response, sexual desire, frequency of activity, and overall satisfaction and orgasm. The majority of research does not show a connection between testosterone and breast cancer, making TRT a possible menopausal treatment for women who cannot use estrogen therapy. [16]

A 2015 report discusses the possible cardiovascular effects of testosterone for women, as well as enhancements for cognitive performance and musculoskeletal health in postmenopausal women. [17]

Regarding future testosterone therapy studies, 2019 should also be a promising year. HGH Doctor looks forward to keeping you informed of the latest research. At this time, we believe testosterone therapy to be extremely safe for men and women following proper diagnostic procedures.

For more information on testosterone replacement therapy, please contact our hormone clinic for a free and confidential consultation.

Research has shown testosterone replacement therapy to be extremely safe and highly effective for treating symptoms of Low T.

More:
Testosterone Replacement Therapy Studies 2019

Recommendation and review posted by Alexandra Lee Anderson


Page 21234..1020..»